blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3129059

EP3129059 - NOVEL COMBINATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL) ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-G][1,2,3]BENZOTRIAZINE-4,9-DIONEAND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  08.03.2019
Database last updated on 14.09.2024
FormerRequest for examination was made
Status updated on  13.01.2017
FormerThe international publication has been made
Status updated on  02.11.2016
Most recent event   Tooltip08.03.2019Application deemed to be withdrawnpublished on 10.04.2019  [2019/15]
Applicant(s)For all designated states
Les Laboratoires Servier
35, rue de Verdun
92284 Suresnes Cedex / FR
[2017/07]
Inventor(s)01 / BRETIN, Sylvie
37 Rue Pierre et Marie Curie
F-92160 Antony / FR
02 / PUEYO, Maria
2 Boulevard Arago
F-75013 Paris / FR
 [2017/07]
Application number, filing date15719502.503.04.2015
[2017/07]
WO2015FR50879
Priority number, dateFR2014005304607.04.2014         Original published format: FR 1453046
[2017/07]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2015155451
Date:15.10.2015
Language:FR
[2015/41]
Type: A1 Application with search report 
No.:EP3129059
Date:15.02.2017
Language:FR
The application published by WIPO in one of the EPO official languages on 15.10.2015 takes the place of the publication of the European patent application.
[2017/07]
Search report(s)International search report - published on:EP15.10.2015
ClassificationIPC:A61K45/06, A61K31/445, A61K31/5365, A61P25/28, A61K9/00, A61K31/27, A61K31/55
[2017/07]
CPC:
A61K31/5365 (EP,CN,KR,US); A61K45/06 (EP,CN,KR,US); A61K31/27 (EP,CN,KR,US);
A61K31/445 (EP,CN,KR,US); A61K31/55 (EP,CN,KR,US); A61K9/2013 (EP,KR,US);
A61K9/2018 (EP,KR,US); A61K9/2054 (US); A61K9/2059 (EP,CN,KR,US);
A61P25/00 (EP); A61P25/28 (EP); A61P43/00 (EP);
A61K2300/00 (KR) (-)
C-Set:
A61K31/27, A61K2300/00 (US,CN,EP);
A61K31/445, A61K2300/00 (US,CN,EP);
A61K31/5365, A61K2300/00 (EP,CN,US);
A61K31/55, A61K2300/00 (US,CN,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/07]
Extension statesBA30.09.2016
ME30.09.2016
Validation statesMA30.09.2016
TitleGerman:NEUARTIGE KOMBINATION ZWISCHEN 8-CYCLOPROPYL-3-[2-(3-FLUORPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-G][1,2,3]BENZOTRIAZIN-4,9-DION UND ACETYLCHOLINESTERASE-INHIBITOREN SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT[2017/07]
English:NOVEL COMBINATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL) ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-G][1,2,3]BENZOTRIAZINE-4,9-DIONEAND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME[2017/07]
French:NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL) ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-G][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN INHIBITEUR DE L'ACETYLCHOLINESTERASE, ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CELLE-CI[2017/07]
Entry into regional phase30.09.2016National basic fee paid 
30.09.2016Designation fee(s) paid 
30.09.2016Examination fee paid 
Examination procedure30.09.2016Examination requested  [2017/07]
30.09.2016Date on which the examining division has become responsible
05.05.2017Amendment by applicant (claims and/or description)
01.11.2018Application deemed to be withdrawn, date of legal effect  [2019/15]
29.11.2018Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2019/15]
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
30.04.201804   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2005072345  (CORTEX PHARMA INC [US], et al) [Y] 1-15 * paragraph [0017] - paragraph [0019]; figure -; example -; claim - * * paragraph [0048] * * paragraph [0063] - paragraph [0070] * * paragraph [0072] * * paragraph [0091] *;
 [YD]WO2008085506  (CORTEX PHARMA INC [US], et al) [YD] 1-15 * claim - *;
 [Y]WO2009038752  (CORTEX PHARMA INC [US], et al) [Y] 1-15 * page 5, line 20 - page 6, line 10; claim 27 *;
 [Y]  - SIMON J. A. GROVE ET AL, "Positive Allosteric Modulators of the [alpha]-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor", JOURNAL OF MEDICINAL CHEMISTRY, (20101028), vol. 53, no. 20, doi:10.1021/jm1000419, ISSN 0022-2623, pages 7271 - 7279, XP055141406 [Y] 1-15 * page 7271, column 2, line 11 * * page 7274, column 2, paragraph 1 * * table 1; compound 12 *

DOI:   http://dx.doi.org/10.1021/jm1000419
by applicantWO2008085506
    - ROBBINS ET AL., TRENDS IN PHARMACOL. SCI., (2006), vol. 27, no. 3, pages 141 - 148
    - ADVOKAT ET AL., NEUROSCIENCE & BIOBEHAV. REV., (1992), vol. 16, pages 13 - 24
    - FRANCIS ET AL., PROGRESS IN NEUROBIOLOGY, (1992), vol. 39, no. 5, pages 517 - 545
    - BLACK, P.SYCHOPHARMACOL., (2005), vol. 179, pages 154 - 163
    - O'NEILL ET AL., IDRUGS, (2007), vol. 10, no. 3, pages 185 - 192
    - YUEDE ET AL., BEHAV. PHARMACOL., (2007), vol. 18, no. 5-6, pages 347 - 363
    - CÉLÉRIER ET AL., LEARN ME, (2004), vol. 11, no. 2, pages 196 - 204
    - TRONCHE ET AL., E AV. BRAIN RES., (2010), vol. 215, no. 2, pages 255 - 260
    - GOLD ET AL., EXPERT REV. NEUROTHER., (2008), vol. 8, no. 12, pages 1879 - 1891
    - SHAPIRO, RCH. NEUROL., (2001), vol. 58, pages 874 - 881
    - GRUART ET AL., ! NEUROSCI., (2006), vol. 24, pages 1077 - 1087
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.